Aardvark Therapeutics (AARD) closed at $1.26 on November 16, 2026, down 5.3% from the previous close, on volume of 208,917 shares (30-day average 1,180,136).
Data as of November 16, 2026.
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
TipRanks (Mon, 16-Nov 8:46 PM ET)
TipRanks (Sun, 15-Nov 7:50 PM ET)
Aardvark Therapeutics GAAP EPS of -$0.88
Seeking Alpha News (Fri, 13-Nov 8:47 AM ET)
Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Fri, 13-Nov 8:00 AM ET)
Globe Newswire (Mon, 2-Nov 9:51 AM ET)
Globe Newswire (Fri, 30-Oct 8:55 AM ET)
Market Chameleon (Tue, 27-Oct 6:28 AM ET)
Globe Newswire (Mon, 26-Oct 8:51 AM ET)
Globe Newswire (Fri, 23-Oct 7:00 AM ET)
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Aardvark Therapeutics trades on the NASDAQ stock market under the symbol AARD.
As of November 17, 2026, AARD stock price declined to $1.17 with 410,764 million shares trading.
AARD has a beta of 5.20, meaning it tends to be more sensitive to market movements. AARD has a correlation of 0.17 to the broad based SPY ETF.
AARD has a market cap of $25.61 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that AARD belongs to (by Net Assets): VTI, VXF, IBB, IWC, BUSM.
AARD has underperformed the market in the last year with a return of -88.2%, while the SPY ETF gained +10.0%. In the last 3 month period, AARD fell short of the market, returning -82.1%, while SPY returned -5.5%. However, in the most recent 2 weeks AARD has outperformed the stock market by returning -2.5%, while SPY returned -2.7%.
AARD support price is $1.13 and resistance is $1.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AARD shares will trade within this expected range on the day.